A Phase 2A, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Sequential, Dose-Ascending Study Of CC-220 In Subjects With Chronic Cutaneous Sarcoidosis

Trial Profile

A Phase 2A, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Sequential, Dose-Ascending Study Of CC-220 In Subjects With Chronic Cutaneous Sarcoidosis

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 04 Oct 2016

At a glance

  • Drugs Iberdomide (Primary)
  • Indications Sarcoidosis
  • Focus Adverse reactions
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 27 Jan 2015 Status changed from not yet recruiting to withdrawn prior to enrolment, according to ClinicalTrials.gov record
    • 18 Jul 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top